Clinical Trial: Adaptive Platform Trial for Pain Management in Sickle Cell Vaso-Occlusive Crisis

U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07826988) titled 'Adaptive Platform Trial for Pain Management in Sickle Cell Vaso-Occlusive Crisis' on July 28.

Brief Summary: Sickle cell disease (SCD) is a severe hemoglobinopathy, characterized by recurrent vaso-occlusive crises (VOC) causing intense pain and frequent hospitalizations in adult patients. Current French and British guidelines recommend rapid administration of strong opioids, primarily through patient-controlled analgesia (PCA), as the reference treatment for hospitalized patients experiencing VOC. However, opioid use is associated with dose-dependent adverse effects, including nausea, constipation, pruritus, sedation, and hypoventi...